|
Press Releases |
|
|
|
Tuesday, April 16, 2024 |
|
中国抗体SM17治疗特应性皮炎(AD)之临床前结果刊登于国际科学期刊《Allergy》 |
more info >> |
|
中國抗體SM17治療特應性皮炎(AD)之臨床前結果刊登於國際科學期刊《Allergy》 |
more info >> |
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
Tuesday, September 12, 2023 |
|
中国抗体SM17新药研究申请再获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗特应性皮炎(“AD”)的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”) more info >> |
|
中國抗體SM17新藥研究申請再獲國家藥監局批准 |
專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司(上市編號:3681.HK,下稱「中國抗體」或「本公司」)欣然宣佈,本公司所提交之治療特應性皮炎(「AD」)的同類首創(First-in-Class)治療產品SM17的新藥研究申請(「新藥研究申請」) more info >> |
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, August 14, 2023 |
|
中国抗体SM17针对治疗哮喘疾病的新药研究申请获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗哮喘的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”)于2023年8月11日获中国国家药品监督管理局(“国家药监局”)批准。 more info >> |
|
中國抗體SM17針對治療哮喘疾病的新藥研究申請獲國家藥監局批准 |
專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司(上市編號:3681.HK,下稱「中國抗體」或「本公司」)欣然宣佈,本公司所提交之治療哮喘的同類首創(First-in-Class)治療產品SM17的新藥研究申請(「新藥研究申請」)於2023年8月11日獲中國國家藥品監督管理局(「國家藥監局」)批准。 more info >> |
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, June 12, 2023 |
|
中国抗体SM17再增一项适应症研究申请 针对治疗特应性皮炎(AD)的新药研究申请获国家药监局药品审评中心受理 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,SM17(注射用人源化抗IL-17RB单克隆抗体)针对治疗特应性皮炎(AD)的新药研究申请已于6月9日获中国国家药品监督管理局(“国家药监局”)药品审评中心受理。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Honda、新型SUV「WR-V」受注状況について
Apr 24, 2024 10:00: JST
|
|
|
三菱みなとみらい技術館に「空・宇宙ゾーン」を新設、リニューアルオープン
Apr 24, 2024 10:00: JST
|
|
|
Masverse Unveils Groundbreaking Blockchain Platform
Apr 24, 2024 09:37: JST
|
|
|
Dogs Thrive on Vegan Diets, Demonstrates the Most Comprehensive Study So Far
Apr 24, 2024 07:00 HKT/SGT
|
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 23:06: JST
|
|
|
Graid Technology Announces Software Update, Delivers Enhanced Levels of Data Integrity and Business Continuity
Apr 23, 2024 23:00 HKT/SGT
|
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 22:00 HKT/SGT
|
|
|
GA-ASI Mojave Lights Up the Yuma Desert in Live-Fire Demonstration
Apr 23, 2024 20:00 HKT/SGT
|
|
|
2024 U.S. Open Polo Championship(R) Closes Out Historic High-Goal Season at the Sport's Premier Destination in Palm Beach County, Florida
Apr 23, 2024 20:00 HKT/SGT
|
|
|
HKTDC Home InStyle, Fashion InStyle forge global business opportunities
Apr 23, 2024 19:00 HKT/SGT
|
|
|
Masverse Unveils Groundbreaking Blockchain Platform
Apr 23, 2024 18:00 HKT/SGT
|
|
|
Dubai Sets the Stage for Digital Innovation: Unveiling the Inaugural Digital Transformation Summit
Apr 23, 2024 17:56 HKT/SGT
|
|
|
New Contaminants, Food Testing & More: analytica Convention 2024 Focuses on Vietnam's Laboratory Needs
Apr 23, 2024 16:00 HKT/SGT
|
|
|
多元产品夯实核心竞争力 泛娱乐产品龙头卡游拟赴港IPO
Apr 23, 2024 15:25 HKT/SGT
|
|
|
多元產品夯實核心競爭力 泛娛樂產品龍頭卡游擬赴港IPO
Apr 23, 2024 15:20 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|